MedTrace Logo

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

NCT01211860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2014-01-10

No results posted yet for this study

Summary

Once a day oral administration with DCCR is the optimal dosing regimen

Conditions

  • Hypertriglyceridmia

Interventions

DRUG

Diazoxide Choline Controlled-Release Tablet

DCCR 290 mg once a day for 10 days

Sponsors & Collaborators

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Essentialis, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan K Copa, PharmD · Cetero Research - Fargo, ND

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01211860 on ClinicalTrials.gov